Molecular Targets Phase III CoBRE

描述（由申请人提供）：路易斯维尔大学生物医学研究卓越分子靶点中心（MT COBRE）和詹姆斯·格雷厄姆·布朗癌症中心在其第一阶段和第二阶段资助期间成功地支持了14名初级教师的早期职业生涯。目前的应用反映了分子靶标程序及其教员的成熟。分子靶标COBRE III期应用的总体目标是确保由MT COBRE团队鉴定的新靶标和化合物转化为关键的人体临床试验。该项目成功的几个优势包括：1)项目领导的稳定性；2)成功保留所有14名教职员工；3)机构支持项目总额超过3000万美元；4)成立一家由路易斯维尔大学所有的公司，专门翻译MT COBRE研究人员的重要发现。MT COBRE教师在人体中测试他们的新化合物的能力将使这个项目与其他机构的类似项目区别开来。”为此，MT COBRE支持开发独特的转化研究基础设施，使30多个新目标的表征成为可能。三期申请将密切支持这四家公司

DESCRIPTION (provided by applicant): The Molecular Targets Center of Biomedical Research Excellence (MT COBRE) at the University of Louisville and the James Graham Brown Cancer Center has successful supported the early career of fourteen junior faculty members during its Phase I and il funding periods. The current application reflects the maturation of the Molecular Targets Program and its faculty. The overall goal of the Phase III application of the Molecular Targets COBRE will be to ensure that the novel targets and compounds which have been identified by MT COBRE faculty are translated to pivotal human clinical trials. Several strengths have enhanced the success of this program including: 1) Stability of program leadership; 2) Successful retention of all fourteen faculty members; 3) Institutional support for the program totaling over $30M; and 4) Creation of a University of Louisville-owned company dedicated to translating important discoveries of MT COBRE investigators. The ability of MT COBRE faculty to test their novel compounds in humans will distinguish this program from similar programs at other institutions.' To this end, the MT COBRE has supported the development of a unique translational research infrastructure which has enabled the characterization of more than 30 novel targets. The Phase III application will support four closely integrated core facilities which will support this goal; 1) Microarray Core; 2) Molecular Modeling Core; 3) NMR/Metabolomic Core and 4) Animal Model Core. Additionally, the James Graham Brown Cancer Center has created complementary research cores which will be available to MT Program members during the Phase III component of the program including the Biostatistics Core, Clinical Trials Office, Biophysical Cancer Core, Cell Sorting and Flow Cytometry Core. The MT COBRE administration will continue to provide intensive support for development of the fourteen faculty members, many of whom have assumed leadership roles within the Cancer Center and University. The robust translational research infrastructure at the James Graham Brown Cancer Center and University of Louisville will ensure the success and sustainability of this unique program.